S&P 500   3,377.36 (+0.50%)
DOW   28,056.82 (+0.95%)
QQQ   270.22 (-0.03%)
AAPL   446.85 (-0.90%)
MSFT   207.28 (-0.47%)
FB   265.11 (+0.80%)
GOOGL   1,507.62 (+0.72%)
AMZN   3,150.66 (+0.08%)
NVDA   443.08 (-0.79%)
CGC   17.62 (-1.73%)
BABA   252.17 (+1.62%)
TSLA   1,414.53 (-0.28%)
GE   6.86 (+2.85%)
MU   48.69 (-0.94%)
AMD   79.88 (-2.87%)
T   30.36 (+0.53%)
F   7.27 (+2.54%)
ACB   10.10 (-1.17%)
GILD   68.36 (-0.22%)
NFLX   477.47 (-1.22%)
DIS   131.29 (+1.94%)
BAC   27.32 (+2.86%)
BA   185.80 (+3.56%)
S&P 500   3,377.36 (+0.50%)
DOW   28,056.82 (+0.95%)
QQQ   270.22 (-0.03%)
AAPL   446.85 (-0.90%)
MSFT   207.28 (-0.47%)
FB   265.11 (+0.80%)
GOOGL   1,507.62 (+0.72%)
AMZN   3,150.66 (+0.08%)
NVDA   443.08 (-0.79%)
CGC   17.62 (-1.73%)
BABA   252.17 (+1.62%)
TSLA   1,414.53 (-0.28%)
GE   6.86 (+2.85%)
MU   48.69 (-0.94%)
AMD   79.88 (-2.87%)
T   30.36 (+0.53%)
F   7.27 (+2.54%)
ACB   10.10 (-1.17%)
GILD   68.36 (-0.22%)
NFLX   477.47 (-1.22%)
DIS   131.29 (+1.94%)
BAC   27.32 (+2.86%)
BA   185.80 (+3.56%)
S&P 500   3,377.36 (+0.50%)
DOW   28,056.82 (+0.95%)
QQQ   270.22 (-0.03%)
AAPL   446.85 (-0.90%)
MSFT   207.28 (-0.47%)
FB   265.11 (+0.80%)
GOOGL   1,507.62 (+0.72%)
AMZN   3,150.66 (+0.08%)
NVDA   443.08 (-0.79%)
CGC   17.62 (-1.73%)
BABA   252.17 (+1.62%)
TSLA   1,414.53 (-0.28%)
GE   6.86 (+2.85%)
MU   48.69 (-0.94%)
AMD   79.88 (-2.87%)
T   30.36 (+0.53%)
F   7.27 (+2.54%)
ACB   10.10 (-1.17%)
GILD   68.36 (-0.22%)
NFLX   477.47 (-1.22%)
DIS   131.29 (+1.94%)
BAC   27.32 (+2.86%)
BA   185.80 (+3.56%)
S&P 500   3,377.36 (+0.50%)
DOW   28,056.82 (+0.95%)
QQQ   270.22 (-0.03%)
AAPL   446.85 (-0.90%)
MSFT   207.28 (-0.47%)
FB   265.11 (+0.80%)
GOOGL   1,507.62 (+0.72%)
AMZN   3,150.66 (+0.08%)
NVDA   443.08 (-0.79%)
CGC   17.62 (-1.73%)
BABA   252.17 (+1.62%)
TSLA   1,414.53 (-0.28%)
GE   6.86 (+2.85%)
MU   48.69 (-0.94%)
AMD   79.88 (-2.87%)
T   30.36 (+0.53%)
F   7.27 (+2.54%)
ACB   10.10 (-1.17%)
GILD   68.36 (-0.22%)
NFLX   477.47 (-1.22%)
DIS   131.29 (+1.94%)
BAC   27.32 (+2.86%)
BA   185.80 (+3.56%)
Log in

NASDAQ:ATHXAthersys Stock Price, Forecast & News

$2.37
-0.22 (-8.49 %)
(As of 08/11/2020 12:45 PM ET)
Add
Compare
Today's Range
$2.31
Now: $2.37
$2.49
50-Day Range
$1.97
MA: $2.72
$3.08
52-Week Range
$1.13
Now: $2.37
$4.38
Volume52,766 shs
Average Volume2.74 million shs
Market Capitalization$465.66 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.7
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke; and that is in Phase II clinical study for the treatment of patients with acute myocardial infarction, as well as that has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical need. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases. It also has license and collaboration agreements with RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; the University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Read More
Athersys logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.97 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATHX
CUSIPN/A
Phone216-431-9900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.63 million
Book Value$0.15 per share

Profitability

Net Income$-44,580,000.00

Miscellaneous

Employees75
Market Cap$465.66 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$2.37
-0.22 (-8.49 %)
(As of 08/11/2020 12:45 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATHX News and Ratings via Email

Sign-up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Athersys (NASDAQ:ATHX) Frequently Asked Questions

How has Athersys' stock been impacted by Coronavirus?

Athersys' stock was trading at $1.28 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ATHX stock has increased by 93.8% and is now trading at $2.48.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Athersys?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Athersys
.

When is Athersys' next earnings date?

Athersys is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Athersys
.

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) posted its earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.02.
View Athersys' earnings history
.

What price target have analysts set for ATHX?

4 analysts have issued 12 month target prices for Athersys' stock. Their forecasts range from $5.00 to $14.00. On average, they expect Athersys' stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 262.9% from the stock's current price.
View analysts' price targets for Athersys
.

Has Athersys been receiving favorable news coverage?

News stories about ATHX stock have trended neutral on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Athersys earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Athersys
.

Who are some of Athersys' key competitors?

What other stocks do shareholders of Athersys own?

Who are Athersys' key executives?

Athersys' management team includes the following people:
  • Dr. Gil Van Bokkelen, Co-Founder, Chairman & CEO (Age 58)
  • Mr. William B. J. Lehmann Jr., M.B.A., J.D., MBA, Pres, COO & Sec. (Age 53)
  • Dr. John J. Harrington, Co-Founder, Chief Scientific Officer, Exec. VP & Director (Age 52)
  • Ms. Laura K. Campbell, Sr. VP of Fin. (Age 55)
  • Karen Hunady, Director of Corp. Communications & Investor Relations

What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

Who are Athersys' major shareholders?

Athersys' stock is owned by a variety of retail and institutional investors. Top institutional investors include Coastal Investment Advisors Inc. (0.44%), GW&K Investment Management LLC (0.29%), Swiss National Bank (0.21%), M&G Investment Management Ltd. (0.11%), Cedar Brook Financial Partners LLC (0.10%) and NEXT Financial Group Inc (0.09%). Company insiders that own Athersys stock include John J Harrington, Kenneth H Traub, Laura K Campbell and William Lehmann Jr.
View institutional ownership trends for Athersys
.

Which major investors are selling Athersys stock?

ATHX stock was sold by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., Russell Investments Group Ltd., and MAI Capital Management. Company insiders that have sold Athersys company stock in the last year include John J Harrington, Laura K Campbell, and William Lehmann Jr.
View insider buying and selling activity for Athersys
.

Which major investors are buying Athersys stock?

ATHX stock was purchased by a variety of institutional investors in the last quarter, including Swiss National Bank, Rafferty Asset Management LLC, Coastal Investment Advisors Inc., New York State Common Retirement Fund, State Board of Administration of Florida Retirement System, Nisa Investment Advisors LLC, GW&K Investment Management LLC, and Arizona State Retirement System.
View insider buying and selling activity for Athersys
.

How do I buy shares of Athersys?

Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Athersys' stock price today?

One share of ATHX stock can currently be purchased for approximately $2.48.

How big of a company is Athersys?

Athersys has a market capitalization of $487.27 million and generates $5.63 million in revenue each year. The biopharmaceutical company earns $-44,580,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Athersys employs 75 workers across the globe.

What is Athersys' official website?

The official website for Athersys is www.athersys.com.

How can I contact Athersys?

Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at 216-431-9900 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.